Partnership18 Sept 2026, 09:01 am
Dr Reddy's Partners Takeda for Dengue Vaccine Distribution in India
AI Summary
Dr. Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga®, a dengue vaccine. This collaboration focuses on the private market in India, with Dr. Reddy's handling distribution and marketing, and Takeda retaining commercialization rights in the public market, along with manufacturing and importation. The vaccine, approved by CDSCO for individuals aged 4-60 years, is expected to be available in the first half of 2027. This partnership aims to strengthen Dr. Reddy's vaccine business and contribute to dengue prevention efforts in India.
Key Highlights
- Dr. Reddy's to distribute and market Takeda's Qdenga® dengue vaccine in India's private market.
- Qdenga® is India's first CDSCO-approved dengue vaccine.
- Vaccine expected to be available in the first half of 2027.
- Partnership aligns with Dr. Reddy's strategy to expand its vaccine business.
- No upfront consideration or milestone payments involved.
Price Impact
More from DRREDDY